The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
News & Analysis: Coherus BioSciences
CHRS earnings call for the period ending June 30, 2020.
Volatile stock market or not, these two drug developers are well positioned for long-term success.
The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.
CHRS earnings call for the period ending March 31, 2020.
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
CHRS earnings call for the period ending December 31, 2019.
These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.
The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.
CHRS earnings call for the period ending September 30, 2019.